Picotamide

Summary

Picotamide is a platelet aggregation inhibitor. It works as a thromboxane synthase inhibitor and a thromboxane receptor inhibitor, the latter by modifying cellular responses to activation of the thromboxane receptor.[1] Picotamide is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.[2]

Picotamide
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-methoxy-N,N'-bis(pyridin-3-ylmethyl)isophthalamide
CAS Number
  • 32828-81-2 checkY
    80530-63-8 (monohydrate)
PubChem CID
  • 4814
ChemSpider
  • 4649 checkY
UNII
  • 654G2VCI4Q
CompTox Dashboard (EPA)
  • DTXSID40186498 Edit this at Wikidata
ECHA InfoCard100.046.572 Edit this at Wikidata
Chemical and physical data
FormulaC21H20N4O3
Molar mass376.416 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(NCc1cccnc1)c3cc(C(=O)NCc2cccnc2)c(OC)cc3
  • InChI=1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27) checkY
  • Key:KYWCWBXGRWWINE-UHFFFAOYSA-N checkY
  (verify)

References edit

  1. ^ Ratti S, Quarato P, Casagrande C, Fumagalli R, Corsini A (August 1998). "Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes". European Journal of Pharmacology. 355 (1): 77–83. doi:10.1016/S0014-2999(98)00467-1. PMID 9754941.
  2. ^ Capra V, Bäck M, Angiolillo DJ, Cattaneo M, Sakariassen KS (February 2014). "Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation". Journal of Thrombosis and Haemostasis. 12 (2): 126–137. doi:10.1111/jth.12472. PMID 24298905.

Further reading edit

  • Celestini A, Violi F (2007). "A review of picotamide in the reduction of cardiovascular events in diabetic patients". Vascular Health and Risk Management. 3 (1): 93–8. PMC 1994050. PMID 17583179.